Findings of IDEA Collaboration Have Influenced Prescribing Patterns
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 9, 2023 -- Changes in prescribing patterns for resected stage III colon cancer have been observed since the abstract presentation of the IDEA collaboration in June 2017, according to a study published online Aug. 7 in the Journal of the National Comprehensive Cancer Network.
Fang-Shu Ou, Ph.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the impact of results of the IDEA collaboration, which aimed to evaluate whether three months of adjuvant chemotherapy was noninferior to six months for patients with resected stage III colon cancer. The primary end point was not met, but subgroup analyses demonstrated noninferiority in a risk-stratified approach. Prescribing patterns were examined prior to presentation of the abstract in June 2017 and after manuscript publication in March 2018. The analysis included 399 patients with stage III colon cancer who received adjuvant chemotherapy.
The researchers observed a significant increasing trend for use of three months of adjuvant chemotherapy after presentation of the IDEA abstract. There was also a significant change in capecitabine/oxaliplatin (CAPOX) prescribing from 14 to 48 percent of patients prior to abstract presentation and after presentation. Over time, there was a steady increase in three months of CAPOX use compared with six months of fluorouracil/leucovorin/oxaliplatin (adjusted odds ratio, 1.28). No differences in adoption of CAPOX were observed among subgroups of interest. Similar adoption of three months of CAPOX was seen with low- and high-risk cancer (adjusted odds ratios, 1.27 and 1.31, respectively).
"The findings have influenced practice prescribing patterns, favoring CAPOX and a shorter duration of planned adjuvant treatment," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Extending Interval Between Colonoscopies Feasible After Negative Result
FRIDAY, May 3, 2024 -- For individuals without a family history of colorectal cancer (CRC), increasing the interval between colonoscopies for those with a first colonoscopy with...
Aspirin May Enhance Immunosurveillance Against Colorectal Cancer
MONDAY, April 22, 2024 -- Aspirin may promote an immune response against cancer, with fewer nodal metastases and higher infiltration of tumor-infiltrating lymphocytes among...
Mortality Down for Rectal Cancer Surgery at NAPRC-Accredited Hospitals
FRIDAY, April 19, 2024 -- National Accreditation Program for Rectal Cancer (NAPRC)-accredited hospitals have lower risk-adjusted mortality and morbidity for patients undergoing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.